Zika vaccine candidate shows promise in phase I trial
Strengthening capacities and resource allocation for co-production of health research in low and middle income countries
16 February 2021Hospitals still ration medical N95 masks as stockpiles swell
16 February 2021Zika vaccine candidate shows promise in phase I trial
The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine.
